Your browser doesn't support javascript.
loading
Tenascin-C increases lung metastasis by impacting blood vessel invasions.
Sun, Zhen; Velázquez-Quesada, Inés; Murdamoothoo, Devadarssen; Ahowesso, Constance; Yilmaz, Alev; Spenlé, Caroline; Averous, Gerlinde; Erne, William; Oberndorfer, Felicitas; Oszwald, Andre; Kain, Renate; Bourdon, Catherine; Mangin, Pierre; Deligne, Claire; Midwood, Kim; Abou-Faycal, Chérine; Lefebvre, Olivier; Klein, Annick; van der Heyden, Michael; Chenard, Marie-Pierre; Christofori, Gerhard; Mathelin, Carole; Loustau, Thomas; Hussenet, Thomas; Orend, Gertraud.
Affiliation
  • Sun Z; INSERM U1109 - MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy and, the Tumor Microenvironment group, France; Université de Strasbourg, Strasbourg, France; LabEx Medalis, Université de Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbou
  • Velázquez-Quesada I; INSERM U1109 - MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy and, the Tumor Microenvironment group, France; Université de Strasbourg, Strasbourg, France; LabEx Medalis, Université de Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbou
  • Murdamoothoo D; INSERM U1109 - MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy and, the Tumor Microenvironment group, France; Université de Strasbourg, Strasbourg, France; LabEx Medalis, Université de Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbou
  • Ahowesso C; INSERM U1109 - MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy and, the Tumor Microenvironment group, France; Université de Strasbourg, Strasbourg, France; LabEx Medalis, Université de Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbou
  • Yilmaz A; INSERM U1109 - MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy and, the Tumor Microenvironment group, France; Université de Strasbourg, Strasbourg, France; LabEx Medalis, Université de Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbou
  • Spenlé C; INSERM U1109 - MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy and, the Tumor Microenvironment group, France; Université de Strasbourg, Strasbourg, France; LabEx Medalis, Université de Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbou
  • Averous G; Department of Pathology, University Hospital Strasbourg, Strasbourg, France.
  • Erne W; INSERM U1109 - MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy and, the Tumor Microenvironment group, France; Université de Strasbourg, Strasbourg, France; LabEx Medalis, Université de Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbou
  • Oberndorfer F; Department of Pathology, Medical University of Vienna (MUW), Vienna, Austria.
  • Oszwald A; Department of Pathology, Medical University of Vienna (MUW), Vienna, Austria.
  • Kain R; Department of Pathology, Medical University of Vienna (MUW), Vienna, Austria.
  • Bourdon C; Etablissement Français du Sang, INSERM U949, Strasbourg, France.
  • Mangin P; Etablissement Français du Sang, INSERM U949, Strasbourg, France.
  • Deligne C; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
  • Midwood K; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
  • Abou-Faycal C; INSERM U1109 - MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy and, the Tumor Microenvironment group, France; Université de Strasbourg, Strasbourg, France; LabEx Medalis, Université de Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbou
  • Lefebvre O; INSERM U1109 - MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy and, the Tumor Microenvironment group, France; Université de Strasbourg, Strasbourg, France; LabEx Medalis, Université de Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbou
  • Klein A; INSERM U1109 - MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy and, the Tumor Microenvironment group, France; Université de Strasbourg, Strasbourg, France; LabEx Medalis, Université de Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbou
  • van der Heyden M; INSERM U1109 - MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy and, the Tumor Microenvironment group, France; Université de Strasbourg, Strasbourg, France; LabEx Medalis, Université de Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbou
  • Chenard MP; Department of Pathology, University Hospital Strasbourg, Strasbourg, France.
  • Christofori G; Department Medicine, University Basel, Basel, Switzerland.
  • Mathelin C; Department of breast diseases and surgery, Strasbourg University Hospital, Strasbourg, France.
  • Loustau T; INSERM U1109 - MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy and, the Tumor Microenvironment group, France; Université de Strasbourg, Strasbourg, France; LabEx Medalis, Université de Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbou
  • Hussenet T; INSERM U1109 - MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy and, the Tumor Microenvironment group, France; Université de Strasbourg, Strasbourg, France; LabEx Medalis, Université de Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbou
  • Orend G; INSERM U1109 - MN3T, The Microenvironmental Niche in Tumorigenesis and Targeted Therapy and, the Tumor Microenvironment group, France; Université de Strasbourg, Strasbourg, France; LabEx Medalis, Université de Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbou
Matrix Biol ; 83: 26-47, 2019 10.
Article in En | MEDLINE | ID: mdl-31288084
ABSTRACT
Metastasis is a major cause of death in cancer patients. The extracellular matrix molecule tenascin-C is a known promoter of metastasis, however the underlying mechanisms are not well understood. To further analyze the impact of tenascin-C on cancer progression we generated MMTV-NeuNT mice that develop spontaneous mammary tumors, on a tenascin-C knockout background. We also developed a syngeneic orthotopic model in which tumor cells derived from a MMTV-NeuNT tumor. Tumor cells were transfected with control shRNA or with shRNA to knockdown tenascin-C expression and, were grafted into the mammary gland of immune competent, wildtype or tenascin-C knockout mice. We show that stromal-derived tenascin-C increases metastasis by reducing apoptosis and inducing the cellular plasticity of cancer cells located in pulmonary blood vessels invasions (BVI), before extravasation. We characterized BVI as organized structures of tightly packed aggregates of proliferating tumor cells with epithelial characteristics, surrounded by Fsp1+ cells, internally located platelets and, a luminal monolayer of endothelial cells. We found extracellular matrix, in particular, tenascin-C, between the stromal cells and the tumor cell cluster. In mice lacking stromal-derived tenascin-C, the organization of pulmonary BVI was significantly affected, revealing novel functions of host-derived tenascin-C in supporting the integrity of the endothelial cell coat, increasing platelet abundance, tumor cell survival, epithelial plasticity, thereby promoting overall lung metastasis. Many effects of tenascin-C observed in BVI including enhancement of cellular plasticity, survival and migration, could be explained by activation of TGF-ß signaling. Finally, in several human cancers, we also observed BVI to be surrounded by an endothelial monolayer and to express tenascin-C. Expression of tenascin-C is specific to BVI and is not observed in lymphatic vascular invasions frequent in breast cancer, which lack an endothelial lining. Given that BVI have prognostic significance for many tumor types, such as shorter cancer patient survival, increased metastasis, vessel occlusion, and organ failure, our data revealing a novel mechanism by which stromal tenascin-C promotes metastasis in human cancer, may have potential for diagnosis and therapy.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Blood Vessels / Receptor, ErbB-2 / Tenascin / Lung Neoplasms / Mammary Neoplasms, Experimental Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Matrix Biol Journal subject: BIOLOGIA MOLECULAR / BIOQUIMICA Year: 2019 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Blood Vessels / Receptor, ErbB-2 / Tenascin / Lung Neoplasms / Mammary Neoplasms, Experimental Type of study: Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: Matrix Biol Journal subject: BIOLOGIA MOLECULAR / BIOQUIMICA Year: 2019 Document type: Article